Invesco LLC Decreases Holdings in Humana Inc. (NYSE:HUM)

Invesco LLC trimmed its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 47.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,271 shares of the insurance provider's stock after selling 2,023 shares during the quarter. Invesco LLC's holdings in Humana were worth $601,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of HUM. Vanguard Group Inc. raised its position in Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares during the last quarter. Dodge & Cox lifted its position in Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after purchasing an additional 5,264,045 shares during the period. Pzena Investment Management LLC boosted its stake in Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after acquiring an additional 1,103,132 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Humana by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after purchasing an additional 63,562 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Humana by 29.8% in the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock valued at $608,348,000 after acquiring an additional 550,692 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Trading Up 1.7%

HUM stock traded up $3.95 during midday trading on Tuesday, hitting $238.61. The stock had a trading volume of 1,280,492 shares, compared to its average volume of 1,811,425. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The business has a fifty day moving average price of $244.77 and a two-hundred day moving average price of $260.35. Humana Inc. has a 1-year low of $212.45 and a 1-year high of $406.46. The firm has a market cap of $28.80 billion, a P/E ratio of 16.87, a price-to-earnings-growth ratio of 1.81 and a beta of 0.43.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. The firm's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $7.23 EPS. On average, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.48%. Humana's payout ratio is 25.04%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on HUM shares. Bank of America lowered their price target on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a report on Tuesday, June 17th. Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a research report on Thursday, May 1st. Guggenheim began coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target for the company. Mizuho raised their target price on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $280.76.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.